Retatrutide (LY3437943) is an injectable peptide developed by Eli Lilly and the most potent weight loss drug ever tested in clinical trials. It’s precursor semaglutide (brand name, Ozempic) targets one hormone receptor and tirzepatide targets two, retatrutide activates three: GLP-1, GIP, and glucagon. Each of these pathways does something distinct, and together they stack in a way that produces incredible weight loss.
Retatrutide is not yet FDA-approved. Clinical trials are ongoing, with approval expected no earlier than 2027.
Mechanism of Action
Retatrutide is a single peptide molecule engineered to bind to three different receptor types:
- GLP-1 activation reduces appetite, slows gastric emptying, and improves insulin secretion.
- GIP activation enhances post-meal insulin response and further increases appetite suppression, may also improve fat metabolism.
- Glucagon activation increases energy expenditure and promotes fat burning in the liver by raising circulating blood glucose by breaking down the livers reserve of glycogen.
GLP-1 (Glucagon-Like Peptide-1)
GLP-1 is a hormone your gut releases in response to food. It signals fullness to the brain, slows stomach emptying so food moves through you slower, and tells the pancreas to release insulin.
Retatrutide is actually 2.5x less potent at the GLP-1 receptor than the native hormone — but the GIP activation (see below) appears to amplify the appetite suppression effect significantly, so the net result is stronger hunger reduction than GLP-1 alone.
GIP (Glucose-Dependent Insulinotropic Polypeptide)
GIP is the other hormone, released alongside GLP-1 after eating and acts as an early warning signal that food is arriving. Similar to GLP-1 it tells the pancreas to release insulin, signals fullness to the brain but additionally plays a role in how the body stores and processes fat (which is yet not fully understood). For a long time, researchers thought GIP was redundant or even counterproductive, but tirzepatide changed that thinking entirely by showing that combining GIP with GLP-1 produced meaningfully better outcomes than either alone.
Retatrutide has 8.9x greater potency at the GIP receptor compared to native GIP, making it the dominant receptor target by design. The working theory is that GIP amplifies appetite suppression in the brain when combined with GLP-1, and may improve fat metabolism in a way that makes the overall weight loss more efficient. Research published in Cell Metabolism on the preclinical development of retatrutide showed it reduced food intake AND increased energy expenditure, a combination that neither GLP-1 nor GIP achieves alone.
Glucagon
This is what makes retatrutide different from semaglutide and tirzepatide. Glucagon is typically thought of as the opposite of insulin, it raises blood sugar by breaking down the liver's glycogen reserves. That sounds like the last thing you'd want in a metabolic drug. But the GLP-1 component is already keeping blood sugar in check by suppressing glucagon output at the pancreas directly. That frees the glucagon receptor activation to do two things that neither GLP-1 nor GIP can do on their own.
First, increase fatty acid oxidation, meaning the liver gets pushed to burn its own fat rather than store it.
Secondly, glucagon agonism also increases total energy expenditure, your body burns more calories at rest, which is the difference from Tirzepatide and why retatrutide can push weight loss beyond Tirzepatide's ceiling. Glucagon stimulation raises resting heart rate.
Third, glucagon agonism independently improves your lipid profile. For LDL, the mechanism runs through a protein called PCSK9, whose job is to destroy LDL receptors on liver cells after they've been used. Normally PCSK9 limits how many receptors stay active, which limits how fast LDL gets cleared from your blood. Glucagon accelerates PCSK9 degradation, so more receptors survive, more LDL gets pulled out of circulation continuously. LDL drops around 20% as a direct pharmacological effect, separate from weight loss.
Triglycerides improve through a different route. As the liver clears its fat stores and starts functioning properly, it stops overproducing and exporting triglyceride-rich particles into the blood. Clearing liver fat also restores insulin sensitivity, which stops the chronic insulin elevation that was driving overproduction in the first place.
HDL, the so-called good cholesterol, does not meaningfully improve on retatrutide. HDL responds better to zone 1-2 cardio and dietary fat quality. Reta cleans up the bad side of your lipid panel, it doesn't actively build the good side.
Dosage
Retatrutide is injected as a once-weekly subcutaneous. Starting doses are generally 0.5-1 mg and tittered up by 0.5 mg every 4 weeks as needed.
If side effects are significant at any stage, the dose is held for an additional 4 weeks before escalating.
Here's what you can expect
The early weeks are mostly about your body adjusting. Appetite suppression begins almost immediately in many people, feeling full faster, thinking about food less, losing the pull toward eating out of boredom or habit. Actual weight on the scale moves slowly at this stage.
Your wearable starts telling you something is wrong. RHR climbs 5–10 bpm above your baseline, HRV drops, and your recovery scores look bad. Your wearable will flag it as poor recovery or high strain. It isn't. The HRV drop is a mathematical side effect of running a faster resting heart rate, not a sign your recovery system is degrading. It peaks around week 24 then gradually comes back down on its own.
Sleep may also feel off in the early weeks, lighter, more disrupted, harder to get into deep sleep. This is common across the GLP-1 class and tends to settle as your body adjusts.
Zone 1-2 cardio attenuates the RHR increase. Low-intensity steady state keeps your cardiovascular base strong and measurably blunts how high the RHR climbs. Resistance training alone won't do it the same way.
At maintenance doses, weight loss continues. Unlike semaglutide, where curves tend to plateau around the 12-month mark, retatrutide's weight loss trajectory is still descending.
Your lipid panel will start shifting noticeably as you reach higher doses. LDL typically drops around 20%, triglycerides come down alongside it. Both are direct effects of the glucagon component, not just a downstream consequence of losing weight. If you've been struggling with bad lipids despite diet and exercise, a fatty liver quietly sabotaging your metabolism from the inside is often the reason. Retatrutide hits that at the root.
HDL won't move much. That one responds to cardio and diet, not this drug. But cleaning up LDL and triglycerides alone is a meaningful shift for most people.
Also worth mentioning you’ll get reduced alcohol tolerance. GLP-1 slows gastric emptying so alcohol hits faster and harder than before. People get drunk on significantly less than they're used to.
Side effects & risks
Gastrointestinal effects (very common)
Nausea, diarrhea, vomiting, and constipation are the most frequently side effects. These typically stabilize within 8–12 weeks & the biggest reason to start slow.
For nausea management. The day after injection is the worst. Eating tiny high-protein meals helps more than anything else.
Constipation is largely the most annoying side-effect. GLP-1 slows gastric emptying, meaning food moves through the digestive system more slowly than normal. Bloating and a feeling of fullness and pressure in the lower abdomen that doesn't go away. Solutions are hydration, fibre intake, and keeping some physical activity going. Magnesium glycinate before bed also helps. Some people use laxatives on difficult days.
Elevated resting heart rate (very common)
Glucagon receptor activation increases heart rate. Retatrutide raises resting heart rate by 5-10 bpm at the highest dose, peaking around week 24 before declining.
Dopamine down-regulation
Anecdotally but there’s definitely a dopamine down-regulation going on with life in general during reta use. Makes you enjoy food less, but also other many things. Nothing crazy, just less hunger for life and all it’s fruits.
Hair loss & “Reta face”
Telogen effluvium (stress- or shock-induced diffuse hair shedding) comes from rapid weight loss and not the drug itself. Usually temporary but can be significant. Rapid fat loss depletes facial fat pads, giving a gaunt, aged appearance. Very common complaint.
Muscle loss
GLP-1 drugs cause significant lean mass loss alongside fat loss, track your protein intake and make sure you get enough, even tho you don’t feel like eating or you will lose muscle mass.
Fatigue
Due to fat-loss and not the actual drug itself. It’s the price you pay. Mood flattening is also widely reported. Food stops being interesting which is the goal, but some people report it extending into a broader flatness, less motivation, less enjoyment generally. Paired with general fat loss fatigue can be significant.
Pancreatitis (rare)
Pancreatitis is inflammation of the pancreas. The pancreas produces digestive enzymes that get released into the small intestine to break down food. Those enzymes are stored in an inactive form inside the pancreas and only get activated once they reach the intestine. The enzymes are powerful enough to digest protein and fat, which means if they activate while still inside the pancreas, the pancreas starts digesting itself.
Symptoms are typically sudden and hard to miss. Severe pain in the upper abdomen that often radiates to the back, nausea, vomiting, and fever. Acute cases usually resolve with rest, fasting, and fluids. Severe cases can be life threatening and require hospitalization.
The risk exists, but is low. Anyone with a history of pancreatitis should approach this drug with caution.
Heart palpitations
The sensation of your own heartbeat, something you normally never notice. On reta it feels like your heart is pounding harder, fluttering, or racing, most noticeable when lying down at night or sitting quietly. It's the same mechanism as the elevated RHR, GLP-1 and glucagon receptors on the sinus node running the heart slightly faster than your baseline. Not dangerous for healthy people. Zone 1-2 cardio helps, and stop abusing stimulants.
Gallbladder disease
Rapid weight loss of any kind increases the risk of gallstones. Rapid fat loss means mobilizing lots of stored fat, breaking it down from fat tissue and releasing those fatty acids into the bloodstream to be used as fuel. This flood of fatty acids arrives at the liver all at once. The liver processes what it can, but with so much arriving simultaneously it also converts a significant portion into cholesterol-rich bile in an oversaturated gallbladder, crystals start forming, and gallstones develop.
This is not specific to retatrutide but is relevant given the magnitude of weight loss it produces.
Long-term safety data beyond one year of Retatrutide doesn't yet exist.
📋 Blood markers to track (note to self)
- Fasting glucose + fasting insulin + HbA1c — baseline metabolic picture and insulin resistance (HOMA-IR). The full picture fasting glucose alone misses. Check at baseline, 3 months, 6 months, then every 6 months.
- Full lipid panel (LDL, HDL, triglycerides) — baseline before starting, recheck at 3 and 6 months to see the glucagon effect on LDL and triglycerides show up. Then annually if stable.
- ALT + AST — liver enzymes. ALT specifically elevates early with liver fat. Baseline shows how compromised the liver is going in, tracking shows whether glucagon-driven liver fat clearance is working. Check at baseline, 3 months, 6 months.
- Amylase + lipase — pancreatic markers. Baseline before starting given pancreatitis risk. Only recheck if client reports upper abdominal pain.
- Creatinine + eGFR — kidney baseline. GLP-1 drugs have protective kidney effects but need a starting point. Check at baseline and every 6 months.
- CBC (haemoglobin + haematocrit) — rapid weight loss can affect these. Flagging anaemia matters for energy and recovery. Check at baseline and 3 months.
Made with Bullet